Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in Patients With r/r Neurological Autoimmune Diseases

NCT06939166 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Neuromyelitis Optica Spectrum Disorders
Myasthenia Gravis
Multiple Sclerosis
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Autoimmune Encephalitis

Interventions

DRUG: UCAR T-cell

Sponsor

Tianjin Huanhu Hospital

Collaborators

[object Object]